A session at the 2017 NEI Congress emphasized the importance of making an accurate diagnosis in patients presenting symptoms of depression.
A session at the 2017 Neuroscience Education Institute (NEI) Congress presented by Stephen M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego, emphasized the importance of making an accurate diagnosis in patients presenting symptoms of depression.
Several psychiatric disorders are commonly misdiagnosed as major depressive disorder (MDD) but may actually be bipolar disorder, pseudobulbar affect disorder (PBA), and post-traumatic depression (PTD), said the NEI chairman.
Stahl began the session by explaining that individuals with unipolar depression and “a bit of mania,” also known as depression with mixed features (DMX), are more likely to have an eventual diagnosis conversion to bipolar disorder. Indications of this can be seen from many clues across the spectrum including family history of bipolar disorder, suicidality, severe depression, antidepressant remission, and impulse control, said Stahl.
“The prognosis for depression with co-occurring (hypo)mania is much worse than for pure unipolar depression or bipolar depression without mixed features,” said Stahl.
Symptoms most commonly seen in DMX include: irritability, distractibility, psychomotor agitation, racing/crowded thoughts, increased talkativeness, emotional lability, and rumination.
Next, Stahl discussed PBA disorder, which occurs in the context of brain injury, including traumatic brain disorder (TBI), stroke, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. PBA is characterized by uncontrollable, inappropriate laughing or crying. For psychiatrists, the most inclusive term for the disorder is involuntary emotional expression disorder.
Symptoms of the disorder include: pathological crying and laughing, irritability, aggression, and unpredictable and rapidly changing emotions. Treatment for the disorder include selective serotonin reuptake inhibitors and tricyclic antidepressants. Both therapies can help reduce the frequency and severity of PBA episodes and are typically prescribed at lower doses than for depression.
“PBA is often underrecognized, misdiagnosed, and undertreated,” said Stahl. “Only 40% of patients who discuss PBA symptoms with their clinician are diagnosed.”
The reason PBA is so frequently misdiagnosed is because is it often mistaken for depression, explained Stahl. However, there are several distinctions—the duration of a PBA episode is shorter, crying is not congruent with subjective mood in PBA, and other symptoms of depression are not associated with PBA.
For patients with TBI, depression is the most common psychiatric complication, said Stahl. More than 50% of patients with moderate to severe TBI will experience a depressive episode in the first year post injury, and they have a risk of suicide that is 5 times that of the general population.
PTD is an adjustment-based depression that may occur rather than biologically based depression after TBI. The difference between MDD and PTD is that PTD is characterized by more irritability, anger, and aggression versus sadness or fearfulness.
“Symptoms that are seemingly indicative of MDD may actually be manifestations of a different psychiatric illness,” concluded Stahl. “Making an accurate differential diagnosis in patients presenting with symptoms of depression is critical to the implementation of optimal patient care.”
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk
November 21st 2024Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Read More